scholarly journals Clinical Evaluation of Leukotriene Receptor Antagonists in Preventing Common Cold-like Symptoms in Bronchial Asthma Patients

2007 ◽  
Vol 56 (3) ◽  
pp. 263-267 ◽  
Author(s):  
Takahiko Horiguchi ◽  
Daisuke Ohira ◽  
Kashin Kobayashi ◽  
Masahiro Hirose ◽  
Junichi Miyazaki ◽  
...  
Keyword(s):  
Bronchial Asthma ◽  
Clinical Evaluation ◽  
Common Cold ◽  
Receptor Antagonists ◽  
Leukotriene Receptor Antagonists ◽  
Asthma Patients ◽  
Leukotriene Receptor

scholarly journals Effectiveness of leukotriene receptor antagonists in the treatment for atopic pathology in children

2020 ◽  
pp. 38-42
Author(s):  
A. I. Zariankina ◽  
M. Kh. Mirrakhimova ◽  
E. R. Shamsieva
Keyword(s):  
Allergic Rhinitis ◽  
Atopic Dermatitis ◽  
Bronchial Asthma ◽  
Eosinophil Count ◽  
Allergic Diseases ◽  
Receptor Antagonists ◽  
Leukotriene Receptor Antagonists ◽  
Leukotriene Receptor

Objective: to study the effectiveness of leukotriene receptor antagonists in the treatment foratopic pathology in children.Material and methods. 224 children with allergic diseases were prescribed to take montelucast for 3– 6 months.Results. Taking montelucast has lead to positive clinical dynamics in 75 % of the cases.A significant reduction of the eosinophil count was achieved on days 10–15 of the therapy. The Cys-LTC4/D4/E4 indices came to normal after a one-month course of montelucast therapy in 40.3 % of cases in children with bronchial asthma, in 63.3 % of cases in children with allergic rhinitis and in 60.5 % of cases in children with atopic dermatitis.Conclusions. The use of montelucast has significantly enhanced the control incidencerate ofallergic diseases in children.

scholarly journals Inhibition of Common Cold-Induced Aggravation of Childhood Asthma by Leukotriene Receptor Antagonists

2012 ◽  
Vol 61 (3) ◽  
pp. 405-410 ◽  
Author(s):  
Shigemi Yoshihara ◽  
Hironobu Fukuda ◽  
Toshio Abe ◽  
Mitsuhiro Nishida ◽  
Yumi Yamada ◽  
...  
Keyword(s):  
Common Cold ◽  
Childhood Asthma ◽  
Receptor Antagonists ◽  
Leukotriene Receptor Antagonists ◽  
Leukotriene Receptor

scholarly journals Addition of Leukotriene Receptor Antagonists to Inhaled Corticosteroids Improved QOL of Patients with Bronchial Asthma Surveyed in Suburban Tokyo, Japan

2011 ◽  
Vol 60 (4) ◽  
pp. 473-481 ◽  
Author(s):  
Nobuharu Ohshima ◽  
Hirotoshi Matsui ◽  
Yoshinori Matsui ◽  
Masahiro Kawashima ◽  
Masahiro Shimada ◽  
...  
Keyword(s):  
Bronchial Asthma ◽  
Inhaled Corticosteroids ◽  
Receptor Antagonists ◽  
Leukotriene Receptor Antagonists ◽  
Leukotriene Receptor

scholarly journals 195 The Impact of Administration of Leukotriene Receptor Antagonists, Pranlukast-EK to Infants with Bronchial Asthma

2012 ◽  
Vol 5 ◽  
pp. S64-S65
Author(s):  
Norifumi Ogawa ◽  
Kentaro Mikami ◽  
Masahiko Sato ◽  
Kenniti Mezawa ◽  
Satoshi Iwata ◽  
...  
Keyword(s):  
Bronchial Asthma ◽  
Receptor Antagonists ◽  
Leukotriene Receptor Antagonists ◽  
Leukotriene Receptor ◽  
The Impact

scholarly journals TARGET THERAPY OF BRONCHIAL ASTHMA WITH LEUKOTRIENE RECEPTOR AGONISTS

2013 ◽  
Vol 10 (5) ◽  
pp. 46-54
Author(s):  
N M Nenasheva
Keyword(s):  
Bronchial Asthma ◽  
Target Therapy ◽  
Receptor Antagonists ◽  
Cysteinyl Leukotrienes ◽  
Asthma Phenotypes ◽  
Receptor Agonists ◽  
Leukotriene Receptor Antagonists ◽  
Leukotriene Receptor

This article describes the features of asthma phenotypes such as asthma in smokers and asthma and obesity. The role of cysteinyl leukotrienes is discussed in the formation of inflammation in these phenotypes of asthma. The leukotriene receptor antagonists, including montelukast are effective in therapy of this category of patients.

scholarly journals Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma Patients

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Ming-Ju Tsai ◽  
Ping-Hsun Wu ◽  
Chau-Chyun Sheu ◽  
Ya-Ling Hsu ◽  
Wei-An Chang ◽  
...  
Keyword(s):  
Cancer Risk ◽  
Research Database ◽  
Dependent Manner ◽  
Receptor Antagonists ◽  
Leukotriene Receptor Antagonists ◽  
Cysteinyl Leukotriene ◽  
Asthma Patients ◽  
Chemopreventive Effect ◽  
Leukotriene Receptor ◽  
Cysteinyl Leukotriene Receptor

Abstract Previous in vitro and in vivo studies have demonstrated the potential of using cysteinyl leukotriene receptor antagonists (LTRAs) for chemoprevention, but this has not been investigated in any clinical setting. We therefore investigated the chemopreventive effect of LTRAs in a nationwide population-based study. From the Taiwan National Health Insurance Research Database, we enrolled adults with newly-diagnosed asthma between 2001 and 2011. Among these patients, each LTRA user was matched with five randomly-selected LTRA non-users by sex, age, asthma diagnostic year and modified Charlson Comorbidity Index score. We considered the development of cancer as the outcome. Totally, 4185 LTRA users and 20925 LTRA non-users were identified. LTRA users had a significantly lower cancer incidence rate than LTRA non-users did. Multivariable Cox regression analyses adjusting for baseline characteristics and comorbidities showed LTRA use was an independent protecting factor (hazard ratio = 0.31 [95% CI: 0.24–0.39]), and cancer risk decreased progressively with higher cumulative dose of LTRAs. In conclusion, this study revealed that the LTRA use decreased cancer risk in a dose-dependent manner in asthma patients. The chemopreventive effect of LTRAs deserves further study.

Sign in / Sign up

Export Citation Format

Share Document